There is no such thing as a sensitive-skin cosmetic. There is only a cosmetic with evidence that it was designed for sensitive skin — and a great many that were not. The claim has become close to standard equipment on a skincare launch, and the industry shorthand for the formulation approach behind it is “mild and mighty”: keep the performance, remove the provocation. It is a genuinely difficult brief, and it is also a claim with no legal definition, no biomarker and no agreed exclusion list. For a brand owner briefing a contract manufacturer, that combination is the risk. Anyone can print the words. What separates a defensible product from a liability is the evidence file, and most of the questions that produce that file have to be asked before development starts rather than after a sample is approved.
Written and researched by Marcus Tan, Private Label & Beauty Sourcing Consultant · Article type: Independent Editorial · Scope: claim substantiation and OEM/ODM sourcing implications of sensitive-skin positioning, with ASEAN and EU regulatory reference points · Research period: August 2026 · Last reviewed: August 2026 · Corrections: via the site contact page.
Quick answer: what does a “for sensitive skin” claim actually require?
A sensitive-skin claim requires substantiating evidence held with the product information file, not a particular ingredient list, because no regulator defines sensitive skin as a product category. In ASEAN markets a claimed benefit must be justified by technical data or by the formulation itself, and that evidence has to be available for inspection. The practical consequence for a brand owner is that the claim is bought at the testing stage, not the marketing stage: ask a prospective manufacturer which human tolerance study supports the wording you intend to use, and confirm that the tested formula is the one being filled.
Key takeaways
- Sensitive skin is a self-reported sensory condition, not a diagnosis. Published reviews find no reliable diagnostic test and no correlation between reported symptoms and objective signs, with prevalence varying from roughly 23% of women surveyed in China to about 75% reporting some sensitivity in European surveys.
- The claim is regulated, even though the category is not. Under the ASEAN Cosmetic Claim Guideline, any claimed benefit must be justified by technical data or the formulation itself, and the evidence kept with the product information file.
- Several of the marketing moves brands reach for first are restricted in the EU. “Free from allergenic or sensitising substances” is explicitly not allowed, “free from parabens” is treated as denigrating a group of legally permitted ingredients, and “free from perfume” fails if any ingredient performs a perfuming function.
- “Hypoallergenic” is the hardest claim in this family, not the safest — it requires that known allergens and allergen precursors are totally avoided and that the responsible person holds continuously updated evidence of very low allergenic potential.
- Fragrance labelling changed this year: products placed on the EU market from 31 July 2026 must individually declare roughly 80 fragrance allergens rather than 24, which reshapes what a fragranced “sensitive” product can look like on a label.
- The most common sourcing failure is not a bad formula but a broken chain of evidence — a tolerance test run on a formula that was subsequently changed.
Who this is for
This is written for indie founders, private label buyers and product managers who intend to position a product for sensitive, reactive or easily irritated skin and are commissioning it from an external OEM (Original Equipment Manufacturer) or ODM (Original Design Manufacturer) partner. It assumes the decision in front of you is what to demand from a factory and what to put on a label, rather than how to formulate. If you are still choosing the partner itself, the criteria in our guide to evaluating an OEM skincare manufacturer come first; this article is what to add on top once sensitivity is part of the positioning.
Why is there no legal definition of “sensitive skin”?
There is no legal definition because sensitive skin is a self-reported sensory experience rather than a measurable clinical state. The International Forum for the Study of Itch defines it as unpleasant sensations — stinging, burning, pain, itching and tingling — occurring in response to stimuli that should not normally provoke them, in the absence of lesions attributable to a skin disease. Every element of that definition is reported by the person, not observed by an instrument.
The prevalence data shows what that produces. A review published in Frontiers in Medicine found self-declared sensitivity running at about 74.7% in European survey populations, 44.6–77.5% across United States studies, and far lower in parts of Asia — roughly 23% of women surveyed in China reported any sensitivity, against 54.5% in Japan (Misery et al., The Prevalence of Sensitive Skin). A spread that wide across populations with broadly similar skin biology is a strong signal that the measurement is cultural and linguistic as much as physiological. The same review is blunt about the diagnostic position: there is no correlation between sensory symptoms and objective signs, and no reliable test.
This is not an argument that the condition is imaginary. It is an argument about what a brand can prove. A claim that rests on a self-reported experience has to be substantiated through how people respond to the product, which means human tolerance work rather than an ingredient declaration. Brands that assume the claim can be satisfied by excluding a list of unpopular ingredients are solving a marketing problem and leaving the regulatory one open.
What are you actually allowed to say?
The claim wording, not the formula, is what regulators read first — and several of the phrases brands reach for by instinct are restricted. The table below maps the common sensitive-skin claims to what each one demands.
| Claim wording | What it requires | Where it commonly fails |
|---|---|---|
| “For sensitive skin” / “suitable for sensitive skin” | Technical data or formulation-based justification held with the product information file; in practice a human tolerance study on a panel including self-declared sensitive-skin participants | No study at all, or a study run on an earlier version of the formula |
| “Hypoallergenic” | Product designed to minimise allergenic potential; known allergens and allergen precursors totally avoided; scientifically robust and statistically reliable evidence of very low allergenic potential, updated continuously | Treated as a softer synonym for “gentle” when it is in fact the most demanding claim in the set |
| “Fragrance-free” / “free from perfume” | No ingredient in the product may exert a perfuming function, regardless of what else that ingredient does | A masking fragrance used to cover raw-material odour, which makes the product unscented but not fragrance-free |
| “Free from allergenic / sensitising substances” | Not permitted in the EU — complete absence of the risk of an allergic reaction cannot be guaranteed | Used as a headline reassurance on exactly the products most likely to attract complaints |
| “Paraben-free” and similar | Restricted in the EU as a denigrating claim, because certain parabens are safe when used in accordance with the Cosmetics Regulation | Carried over from an older marketing playbook and left on export packaging |
| “Preservative-free” | Should not be used where the product contains an ingredient with a protective effect against micro-organisms that is not listed as a preservative, unless challenge-test evidence supports it | Formulas relying on alcohol or multifunctional ingredients for protection |
| “Soothes eczema”, “calms dermatitis”, “stops irritation” | Outside the cosmetic category entirely — a product presented as treating or preventing disease is not being notified as a cosmetic | Social copy and influencer briefs, which are assessed alongside the label |
The EU positions in that table come from the European Commission’s Technical document on cosmetic claims, whose Annex III governs “free from” claims and Annex IV governs “hypoallergenic”. They sit under Regulation (EU) No 655/2013, which sets six common criteria for cosmetic claims: legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making.
For ASEAN markets the framework is different in form and similar in effect. The ASEAN Cosmetic Claim Guideline, published by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA), sets out a five-step decision process for whether a product and its claims are cosmetic at all, and lists unacceptable claims by product type — for skin products these include preventing or reversing the physiological changes of ageing, removing scars, a numbing effect, and preventing, healing, treating or stopping acne. Notably the guideline also describes how a claim can be legitimately softened with modifiers: “helps to remove oil from skin” and “suitable for oily skin types” are acceptable where an absolute functional claim is not. The same technique is the honest route for sensitive-skin copy — “formulated to minimise the risk of irritation” survives scrutiny in a way that “will not irritate” does not. Where the notification mechanics themselves are unfamiliar, our guide to cosmetic product notification and compliance covers the baseline process.
One further change landed this year and is worth checking against any fragranced product intended for export. Commission Regulation (EU) 2023/1545 expanded the list of fragrance substances requiring individual declaration on the ingredient list from 24 to roughly 80, above 0.001% in leave-on products and 0.01% in rinse-off products. Products placed on the EU market from 31 July 2026 must comply, with stock already in the supply chain given until 31 July 2028 (Regulation (EU) 2023/1545, EUR-Lex). A fragranced product positioned for sensitive skin now carries a visibly longer allergen declaration than the same product did two years ago, which is a positioning problem as much as a compliance one.
What does “mild and mighty” cost, and where does the cost sit?
The industry phrase describes a real tension: an active does its work by interacting with skin, and reducing irritation usually means moderating that interaction. The cost of resolving it sits in development iterations and testing rather than in the raw material bill, which is why sensitive-skin quotations often surprise buyers who were expecting a cheaper formula because it contains “less stuff”.
Three mechanisms drive that, and they are worth separating when reading a quotation.
A narrower formulation space. Excluding common fragrance materials and a set of preservatives does not simply shorten the list; it removes options from every subsequent decision. The remaining preservative system typically works within a tighter pH window, which constrains which actives can be used at which levels, which constrains the emulsifier system. Each constraint costs iterations, and iterations are billed in time.
Testing that a conventional product does not need. Standard stability and preservative-efficacy work is the baseline for any cosmetic — our explainer on what stability testing covers sets out that floor. A sensitive-skin claim adds human tolerance work on top. The established method for irritation and sensitisation potential is the human repeat insult patch test (HRIPT), which runs over roughly six weeks in three phases — induction, rest and challenge — on a panel typically in the range of 50 to 200 subjects. That is a real line item and a real block of calendar time, and it cannot be compressed by paying more.
Packaging that has to do microbiological work. A formula built around a reduced preservative system depends far more heavily on its packaging. Airless pumps, tubes and single-dose formats protect the contents in a way an open jar does not, so the packaging decision stops being purely aesthetic and becomes part of the safety case. Brands that choose a wide-mouth jar for shelf presence and then ask for a preservative-light formula are asking for two incompatible things.
The sequencing lesson mirrors what we found looking at another formulation-led trend, the food-inspired texture wave in cosmetics OEM: the sensory or positioning promise is cheap to write into a brief and expensive to hold through scale-up. Getting the constraint list into the brief early is the highest-leverage thing a buyer can do, and our template for writing a cosmetic product brief is the place to record it.
What evidence should a manufacturer be able to hand over?
A credible sensitive-skin project produces a specific set of documents. Ask for them by name, in writing, before approving development:
- A human tolerance or dermatological compatibility report naming the study type, the panel size, whether participants were self-declared sensitive-skin subjects, and who supervised it.
- The exact formula reference the tolerance study was run on, so it can be matched against the formula on the production specification. This is the single most common break in the chain.
- Preservative efficacy (challenge) test results for the final formula in the final primary packaging, not for the bulk alone.
- Stability data including the intended packaging, with the protocol stated rather than a bare pass certificate.
- A claim substantiation summary mapping each phrase you intend to print to the evidence supporting it — the document a regulator would ask for first.
- An allergen declaration for any fragrance used, in the format required by the markets you intend to sell into.
- A change-control commitment: written confirmation that any raw-material substitution triggers a review of whether the tolerance and challenge results still apply, and who approves that.
Red flags. A manufacturer that offers “dermatologically tested” without naming the study; a tolerance report with no panel size or supervision named; an unwillingness to state which formula version was tested; a quotation that prices a sensitive-skin development identically to a conventional one; a factory that proposes to add a fragrance after the tolerance testing has been completed; and any assurance that a product “cannot cause a reaction”. That last one is not caution — it is a claim the EU guidance rules out on its face, and hearing it from a supplier tells you how much regulatory attention the project will receive. Where the shortlist stage is still open, the Malaysian market view in our roundup of skincare OEM manufacturers in Malaysia is a reasonable starting point for who to put these questions to.
Frequently asked questions
Is “dermatologically tested” a meaningful claim?
Only if the test is specified. The phrase confirms that some form of testing involving a dermatologist took place; it says nothing about the study design, the panel, the duration or the result. Ask which study was run, on how many subjects, whether any of them were self-declared sensitive-skin participants, and what the outcome was. A supplier who cannot answer those four questions is describing a marketing phrase rather than a document.
Does a sensitive-skin product have to be fragrance-free?
No, but the fragrance decision has to be deliberate. A product can be fragranced and still positioned for sensitive skin if the fragrance is built to exclude the individually labelled allergens and the tolerance testing was run on the fragranced version. What does not work is adding a fragrance after testing, or describing a masked product as fragrance-free — a “free from perfume” claim fails where any ingredient exerts a perfuming function, whatever else it does in the formula.
Can a brand rely on the manufacturer’s existing sensitive-skin base?
Often yes, and it is usually faster and cheaper than developing from zero, provided two things are true: the tolerance evidence belongs to the base as you will actually sell it, and the customisation you want does not invalidate that evidence. Adding a fragrance, changing the preservative, or raising an active concentration generally does invalidate it. Ask which changes the manufacturer considers to require retesting before you agree to a modification.
Is “hypoallergenic” safer to use than “for sensitive skin”?
It is the harder claim of the two. Under the EU technical document it requires that the product was designed to minimise allergenic potential, that known allergens and allergen precursors are totally avoided — including substances for which sensitisation data is missing — and that the responsible person holds scientifically robust, statistically reliable evidence of very low allergenic potential that is updated as new data arrives. It also carries no guarantee: the guidance states the claim does not assure the absence of an allergic reaction, and the product must not imply that it does.
Do these EU rules matter for a brand selling only in ASEAN?
They are not binding, but they are the most detailed published reasoning available on these specific claims, and ASEAN regulators work from the same underlying principle that claims must be justified and not misleading. Treating the EU annexes as a substantiation checklist is a practical way to arrive at wording that survives scrutiny in either market. If export is a possibility within the product’s lifetime, aligning at development is far cheaper than reprinting labels later.
How long does a sensitive-skin development take compared with a standard one?
Expect the tolerance testing alone to add roughly six weeks of calendar time on top of the standard development and stability programme, plus additional formulation iterations caused by the narrower ingredient space. There is no reliable universal figure for the total, because it depends on the format, the packaging and how many markets are in scope. The useful comparison is a like-for-like timeline from the same manufacturer for your sensitive-skin brief and for a conventional equivalent.
What happens if a customer reports a reaction after launch?
Your claim substantiation file is what determines whether that becomes a complaint or a problem. Post-market surveillance data also feeds back into the claim — the EU guidance on hypoallergenic explicitly expects the assessment to be updated in light of new data, which means a pattern of complaints is not just a customer-service matter but evidence bearing on whether the claim remains supportable. Agree with your manufacturer in advance who logs reactions and what threshold triggers a formulation or wording review.
Sources and evidence
- Misery L. et al., The Prevalence of Sensitive Skin, Frontiers in Medicine — the IFSI definition, regional prevalence figures and the absence of a reliable diagnostic test.
- European Commission, Technical document on cosmetic claims — Annex III (“free from” claims, including the parabens, perfume and sensitising-substance positions) and Annex IV (“hypoallergenic”).
- Commission Regulation (EU) No 655/2013, EUR-Lex — the six common criteria for the justification of cosmetic claims.
- Commission Regulation (EU) 2023/1545, EUR-Lex — expanded fragrance-allergen labelling and the 31 July 2026 and 31 July 2028 transitional dates.
- NPRA Malaysia, ASEAN Cosmetic Claim Guideline (Annex 1, Part 8) — the five-step decision process, unacceptable claims by product type, and the use of modifiers to soften a claim.
- Azelis Personal Care, “Mild and mighty ingredients that power sensitive skin care” — the distributor trend material that prompted this analysis.
- Further reading, manufacturer perspective: ORIZI Group, What “Make It for Sensitive Skin” Actually Changes in the Lab — a Malaysian contract manufacturer’s account of the same brief from the formulation side.
Limitations and scope
This is an independent editorial analysis of published regulatory guidance and peer-reviewed literature, not laboratory or clinical research. No product, formula or manufacturer was tested for this article. The regulatory positions described are drawn from EU guidance documents and the ASEAN Cosmetic Claim Guideline as published at the time of writing; guidance is revised periodically and national implementation varies, so the applicable regulator should be treated as the authority for your specific market and product. No cost, timeline or panel-size figure here is a quotation — all of them vary materially by manufacturer, format and market scope. The Azelis material referenced is a supplier’s own trend and formulation content and has not been independently verified here.
Update history
August 2026 — first published.
Source / inspired by: Azelis Personal Care, “Mild and mighty ingredients that power sensitive skin care” and the Azelis Personal Care inspiration hub. This article provides general sourcing and claims commentary and is not legal, medical or regulatory advice — confirm claim wording, testing requirements and notification obligations with your manufacturer and the applicable market regulator before launch.